Timing eye injections: could 3, 7, or 14 days before surgery matter?

NCT ID NCT06300918

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether giving anti-VEGF injections 3, 7, or 14 days before surgery makes a difference for people with proliferative diabetic retinopathy, a complication of diabetes that causes abnormal blood vessels in the eye. Participants are randomly assigned to one of three timing groups. Using a new technique that allows fluorescein angiography during surgery, the study will compare how well each timing suppresses these abnormal vessels, aiming to identify the most effective approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
anti-VEGF drugs (injected into the eye before surgery)
What this could lead to
If successful, this could identify the optimal timing for anti-VEGF injections before surgery, potentially improving outcomes for people with proliferative diabetic retinopathy.
What could go wrong
This is a small, early-stage trial, and the results may not apply to all patients. The best timing could vary based on individual factors, and the study may not find a clear difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROLIFERATIVE DIABETIC RETINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sichuan Academy of Medical Science Sichuan Provincial Hosptial

    Chengdu, Sichuan, 610014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.